- Home
- SCOR vs INKT Comparison
SCOR vs INKT Comparison
Compare SCOR & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCOR
- INKT
- Stock Information
- Founded
- SCOR 1999
- INKT 2017
- Country
- SCOR United States
- INKT United States
- Employees
- SCOR N/A
- INKT N/A
- Industry
- SCOR Business Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- SCOR Consumer Discretionary
- INKT Health Care
- Exchange
- SCOR Nasdaq
- INKT Nasdaq
- Market Cap
- SCOR 23.9M
- INKT 28.8M
- IPO Year
- SCOR 2007
- INKT 2021
- Fundamental
- Price
- SCOR $5.84
- INKT $62.86
- Analyst Decision
- SCOR Buy
- INKT Strong Buy
- Analyst Count
- SCOR 2
- INKT 2
- Target Price
- SCOR $10.75
- INKT $37.50
- AVG Volume (30 Days)
- SCOR 22.6K
- INKT 2.4M
- Earning Date
- SCOR 08-05-2025
- INKT 08-12-2025
- Dividend Yield
- SCOR N/A
- INKT N/A
- EPS Growth
- SCOR N/A
- INKT N/A
- EPS
- SCOR N/A
- INKT N/A
- Revenue
- SCOR $354,961,000.00
- INKT N/A
- Revenue This Year
- SCOR $3.36
- INKT N/A
- Revenue Next Year
- SCOR $2.72
- INKT N/A
- P/E Ratio
- SCOR N/A
- INKT N/A
- Revenue Growth
- SCOR N/A
- INKT N/A
- 52 Week Low
- SCOR $4.39
- INKT $4.56
- 52 Week High
- SCOR $15.31
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- SCOR 66.75
- INKT 57.39
- Support Level
- SCOR $4.39
- INKT $6.80
- Resistance Level
- SCOR $5.34
- INKT $7.88
- Average True Range (ATR)
- SCOR 0.32
- INKT 0.40
- MACD
- SCOR 0.09
- INKT 0.02
- Stochastic Oscillator
- SCOR 99.57
- INKT 58.86
About SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.